Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salt-Sensitivity and Immunity Cell Activation
NCT03753204Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Vanderbilt University Medical Center. Primary endpoint: Percent of participants with salt sensitive blood pressure at 3 days. Started Sep 2021; status: completed.
Beyond the preview
Go deeper on NCT03753204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753204.